Rapport Therapeutics, Inc. Common Stock (RAPP)

10.27

(0.88%)

EBITDA Summary of Rapport Therapeutics, Inc. Common Stock

  • Rapport Therapeutics, Inc. Common Stock's latest annual EBITDA in 2023 was -34.66 Million USD , down -248.41% from previous year.
  • Rapport Therapeutics, Inc. Common Stock's latest quarterly EBITDA in 2024 Q2 was -20.59 Million USD , down -22.77% from previous quarter.
  • Rapport Therapeutics, Inc. Common Stock reported an annual EBITDA of -10.35 Million USD in 2022, down 0.0% from previous year.
  • Rapport Therapeutics, Inc. Common Stock reported a quarterly EBITDA of -16.94 Million USD for 2024 Q1, down -27.02% from previous quarter.
  • Rapport Therapeutics, Inc. Common Stock reported a quarterly EBITDA of N/A for 2023 FY, down -248.41% from previous quarter.

Annual EBITDA Chart of Rapport Therapeutics, Inc. Common Stock (2023 - 2022)

Historical Annual EBITDA of Rapport Therapeutics, Inc. Common Stock (2023 - 2022)

Year EBITDA EBITDA Growth
2023 -34.66 Million USD -248.41%
2022 -10.35 Million USD 0.0%

Peer EBITDA Comparison of Rapport Therapeutics, Inc. Common Stock

Name EBITDA EBITDA Difference